Industry Feature: Recent Episodes
ReachMD
Guest: Kathleen M. Buchheit, MD
Guest: Joseph K. Han, MD
Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization,1,2 and patients often continue to have severe symptoms despite therapy.3 Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients.3,4 In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia.
References:
- Mullol J, et al. J Allergy Clin Immunol Pract. 2022;10:1434-1453.e9
- Bhattacharyya N, et al. Laryngoscope. 2019;129:1969-1975.
- van der Veen J, et al. Allergy. 2017;72:282-290.
- Laidlaw TM, et al. J Allergy Clin Immunol Pract. 2021;9:1133-1141.
©2024 Amgen and AstraZeneca. All rights reserved.
US-96000 Last Updated 12/24
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Miguel-Angel Perales, MD
Guest: Anna Sureda, MD, PhD
Unfortunately, the treatment paradigm for acute graft-versus-host disease (aGVHD) has not changed for a couple of decades as steroids remain the first-line treatment.1 However, steroids are not a targeted therapy, and they have many side effects that are not well tolerated by patients, including life-threatening infections.1-3 Given these risks, it is important to know how to manage infections related to immunosuppression and optimize the care of patients with aGVHD. Joining Dr Charles Turck to discuss the current landscape of aGVHD management are Dr Miguel-Angel Perales and Dr Anna Sureda. Dr Miguel-Angel Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, and Dr Sureda is the Head of Clinical Hematology at the University of Barcelona in Spain.
References:
- Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant Cell Ther. 2022;28(10):707.e1-707.e7. doi:10.1016/j.jtct.2022.04.014
- Sullivan PW, Ghushchyan VH, Globe G, Sucher B. Health-related quality of life associated with systemic steroids. Qual Life Res. 2017;26(4):1037-1058.
- García-Cadenas I, Rivera I, Martino R, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow …
Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease.
FA-11319389 12/24
Guest: Donald Kohan, MD, PhD
Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City.
References:
- Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143
- Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023
- Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321
- Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301
- Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670
FA-11319389 12/24
In this brief video, learn more about growing evidence supporting the key role of airway epithelium dysfunction in driving inflammation in CRSwNP.
©2025 Amgen and AstraZeneca. All rights reserved.
US-94728 Last Updated 1/25
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Stephen I. Pelton, MD
In the last two pre-pandemic flu seasons, approximately half of hospitalizations from influenza in the US were in adults 65 and older.1,2 A recent real-world study evaluated the relative effectiveness of adjuvanted influenza vaccine versus high-dose vaccine in preventing test-confirmed influenza hospitalizations in this age group across three flu seasons between 2017 and 2020.3 Dr. Charles Turck sits down with Dr. Stephen Pelton, an author on this study, to explore the findings and their implications for influenza vaccination strategies in older adults. Dr. Pelton is a Professor of Pediatrics at the Boston University Chobanian and Avedisian School of Medicine.
References:
- Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA.
- Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023;11:1525.
- McGovern I, Chastek B, Bancroft T, et al. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons. Int J Infect Dis. …
Host: Jennifer Caudle, DO
Guest: Lori Guyton, MD
Guest: Douglas Scharre, MD
Our understanding of the mechanisms underlying Alzheimer’s disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer’s disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention.1 Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer’s disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin.
Reference:
- Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103:263-293.
© Eisai Inc. 2024. All Rights Reserved.
AD-M2123 November 2024
Host: Jennifer Caudle, DO
Guest: Lori Guyton, MD
Guest: Douglas Scharre, MD
As our understanding of Alzheimer’s disease continues to evolve, it’s critical to understand the clinical and pathologic changes underpinning Alzheimer’s disease as it may be able to help guide early diagnosis and clinically meaningful management decisions.1 That’s why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer’s disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin.
Reference:
- Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386.
© Eisai Inc. 2024. All Rights Reserved.
AD-M2130 November 2024
Host: Jennifer Caudle, DO
Guest: Virginia Kaklamani, MD
Guest: Anne O'Dea, MD
When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there’s uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.
Guest: Scott Gottlieb, MD
Host: Charles Turck, PharmD, BCPS, BCCCP
Patients 50+ with moderate-to-severe plaque psoriasis face adherence challenges, increased risk of comorbidities, and insurance transitions from commercial to Medicare. To learn more about how ILUMYA® (tildrakizumab-asmn) helps address the specific treatment needs of these patients, join Dr. Charles Turck as he speaks with Dr. Scott Gottlieb, a physician at Schweiger Dermatology Group in Exton, Pennsylvania.
Unknown: Arnold Advincula, MD
With over 20 years of experience performing the transabdominal cerclage, Dr. Arnold Advincula, Chief of Gynecologic Specialty Surgery at NewYork-Presbyterian and Columbia, has a deep expertise in helping women with cervical insufficiency achieve successful pregnancies. Through the expanded use of robotics, Dr. Advincula and his team are completing the procedure minimally invasively and with more accuracy and precision. Watch to learn how this advanced technique is transforming gynecologic surgery by reducing recovery time and helping women reach their reproductive goals.
© 2024 NewYork-Presbyterian
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sarah Shizuko Morimoto, PsyD
Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it’s important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City.
Reference:
- American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model
Dr. Morimoto is a paid consultant of Otsuka.
November 2024 US.UNB.X.24.00100
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Steven Maron, MD, MSc
Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.
References:
- The Cancer Genome Atlas Network. Nature. 2014;513:202-209.
- Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125.
- Yang B, et al. J Exp Clin Cancer Res. 2019;38:283.
- American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024.
- Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082.
©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Robert McCarron, MD
Guest: Arwen Podesta, MD
Digital therapeutics are a relatively new and intriguing treatment option in mental health care but translating them from a clinical trial to clinical practice can be challenging. That’s why Drs. Robert McCarron and Arwen Podesta join Dr. Charles Turck to share strategies for incorporating digital therapeutics into clinical practice. Dr. McCarron is a Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine School of Medicine, and Dr. Podesta is the President of the Louisiana Psychiatric Medical Association.
Drs. McCarron and Podesta are consultants for Otsuka.
September 2024 US.UNB.X.24.00073
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Maggie Emerson, DNP, APRN, PMHNP-BC
Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That’s why Dr. Charles Turck speaks with Dr. Maggie Emerson about partnering with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha.
Dr. Emerson is a paid consultant of Otsuka.
September 2024 US.UNB.X.24.00082
Host: Matt Birnholz, MD
Guest: Jennifer L. Payne, MD
Guest: Melissa Simon, MD
Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression.
Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine.
References
- American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188.
- Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(19):575-581.
- Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. J Clin Psychiatry. 2016;77(9):1189-1200.
- Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. …
Guest: Jennifer L. Payne, MD
Guest: Melissa Simon, MD
Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women.
Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine.
References
- American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188.
- Campbell SB, Cohn JF, Meyers T. Depression in First-Time Mothers: Mother-Infant Interaction and Depression Chronicity. Dev Psychol. 1995;31:349-357.
- Moore Simas TA, Huang MY, Patton C, et al. The humanistic burden of postpartum depression: a systematic literature review. Curr Med Res Opin. 2019;35(3):383-393.
- Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257.
Sage Therapeutics and the Sage Therapeutics logo …
Host: Jennifer Caudle, DO
Guest: Samuel R. Wilson, MD
Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine.
References:
- Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/.
- Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7.
- CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/.
Agios Pharmaceuticals, Inc. © 2024
All right reserved.
SCD-US-0095 / June 2024
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jessie Hsieh, MD
Guest: David Isaacson, MD
About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this gap and potentially improve outcomes by screening for more cancer types. Joining Dr. Charles Turck to share their experiences with MCED testing and a real-world patient case are Drs. Jesse Hsieh and David Isaacson. Dr. Hsieh is the Chairman of the Board of Beacon Health System in Indiana, and Dr. Isaacson is an Assistant Professor of Otolaryngology at the Indiana University School of Medicine.
Reference:
- Estimated deaths per year in 2022 from American Cancer Society Cancer Facts and Figures 2022. Available at:
http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/cancer-facts-and-figures-2022.pdf. Data on file GA-2021-0065
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Leigh Anne Cantrell, MD, MSPH
The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with high-risk cervical disease. To learn more about these guidelines and how to apply them in practice, join Dr. Leigh Cantrell, Medical Physician and Fellow in the American College of Obstetrics and Gynecology.
COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 07/24
Host: Matt Birnholz, MD
Guest: Kay Matthews, LCHW
Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with postpartum depression, barriers that can prevent or delay patients from seeking care, and strategies for combatting stigma and ensuring a timely diagnosis.
Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage Therapeutics, Inc.
Sage Therapeutics, Inc. All rights reserved.
Sage Therapeutics ©2024 MRC-PPD-00792 06/2024
Guest: TJ Gan, MD, MBA, MHS, FRCA (UK), FRCA (lre), LicAc
Guest: Dru Riddle, PhD, DNP, CRNA
When it comes to postoperative nausea and vomiting (PONV) management, multimodal, antiemetic therapy based on patients’ risk factors is routinely provided to minimize the incidence, but unfortunately, patients may still develop breakthrough PONV, in which an antiemetic should be administered from a different class from what's given for prevention.1 Barhemsys® (amisulpride) is an FDA-approved antiemetic for the treatment of PONV in patients who have or have not received prophylaxis.2 Learn more about this treatment option along with current management guidelines, key clinical considerations, and a real-world case study with TJ Gan, MD, MBA, MHS, and Dru Riddle, PhD, DNP. Dr. Gan is the Head of the Division of Anesthesiology and Perioperative Medicine, Critical Care, and Pain Medicine at the University of Texas MD Anderson Cancer Center in Houston, and Dr. Riddle is a certified nurse anesthetist at Texas Christian University in Ft. Worth, TX.
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
- Gormley M, et al. Br Dent J. 2022;233(9):780-786.
- Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024
Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: William F.C. Rigby, MD
Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care treatment with glucocorticoids may result in toxicity for some patients. Learn more about these and other diagnostic and treatment challenges as well as other treatment options with Dr. Charles Turck and Dr. William Rigby, Professor of Medicine and of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.
All rights reserved.
MAT-US-2403256 v1.0 - P
Expiration Date 04/16/2025
Guest: Adam Narloch
Guest: Michelle Hermiston, MD, PhD
Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH) and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the Director of the Pediatric Immunotherapy Program at UCSF Benioff Children’s Hospital. Join us as we start our journey into the world of HLH!
© 2024 Sobi, Inc. All Rights Reserved. NP-34329 04/24
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Stone, MD, MPH
Glucocorticoids are often successfully used as the mainstay of treatment for many inflammatory conditions, but adverse events associated with glucocorticoids use are common. Fortunately, there are steps we can take to reduce the risk of glucocorticoid toxicity, like monitoring patients, educating them on the possible side effects, and considering alternative treatments where available. Tune in to learn more about the side effects, risk factors, and prevention strategies with Dr. Charles Turck and Dr. John Stone.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All rights reserved.
MAT-US-2310647 v1.0 - P
Expiration Date 04/16/2025
Guest: Dena Goffman, MD
Dr. Dena Goffman believes that better maternal care requires a proactive, system-wide approach and is making her vision a reality at NewYork-Presbyterian. She focuses on implementing guidelines that standardize care across all of NewYork-Presbyterian’s hospitals. Dr. Goffman has also aided in FDA approval and adoption of a new, ingenious hemorrhage tool and embraced simulations to train and improve the skills of healthcare professionals throughout the labor and delivery process. Join health and science journalist Catherine Price as she speaks with Dr. Dena Goffman, Vice Chair for Quality and Patient Safety and the Associate Chief and Quality Officer for Obstetrics for NewYork-Presbyterian, about how her work has helped establish goals and quality standards for safer labor and delivery.
© 2024 NewYork-Presbyterian
Guest: Pierre Elias, MD
In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose patients before symptoms occur. Join health and science journalist Catherine Price as she speaks with Dr. Pierre Elias, Medical Director of Artificial Intelligence at NewYork-Presbyterian, about the future of technology in medicine.
© 2024 NewYork-Presbyterian
Guest: Michael Kaplitt, MD, PhD
For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery.
© 2024 NewYork-Presbyterian
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arnaud Bourdin, MD, PhD
Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdin. Professor Bourdin is the Head of Pulmonology at the Arnaud de Villeneuve Hospital in Montpellier, France.
TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.
©2024 Amgen and AstraZeneca. All rights reserved. US-83499 Last Updated 1/24
Guest: Conor Liston, MD, PhD
For patients diagnosed with depression for the first time the recommended course of treatment is the same; however, there’s a large patient population for whom these treatments won’t work. So it became increasingly important for Dr. Liston to map the brains of people suffering from major depression to see how it was impacting brain structures and symptoms. The research showed that certain networks expanded in the brains of patients who had depression and pushed into other networks. Learn more about identifying how these symptoms impact the patient’s brains, analyzing the best course for treatments, and how this research could be the key to effectively using transcranial magnetic stimulation to help patients with treatment-resistant depression. Join health and science journalist Catherine Price as she speaks with Dr. Conor Michael Liston, Psychiatrist at NewYork-Presbyterian/Weill Cornell Medicine, to discuss these approaches to help treatment-resistant depression.
© 2024 NewYork-Presbyterian
Guest: Christopher Petit, MD
Pulmonary vein stenosis (PVS) is a rare and challenging heart condition, which narrows blood vessels around the lungs and typically impacts newborn children. Historically, the rates of survival have been low, but with Dr. Petit leading the development of innovative techniques and treatments, the trajectory of patients’ lives could positively change. Join health and science journalist Catherine Price and Dr. Christopher Petit, Co-Director of Children’s Heart Center at NewYork-Presbyterian Morgan Stanely Children’s Hospital and Division Chief of Pediatric Cardiology at Columbia University, to discuss breakthroughs and treatments that are making a big impact on pediatric survival rates.
© 2024 NewYork-Presbyterian
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamie Koprivnikar, MD
Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health.
REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.
REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.
© 2024 Bristol-Myers Squibb Company
2007-US-2300376 03/24
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Victoria Leavitt, PhD
Disease-modifying therapies (DMTs) are an effective option for patients with multiple sclerosis (MS). In fact, a recent study presented at the 2023 joint ECTRIMS-ACTRIMS meeting in Italy found that MS patients being treated with a DMT had better cognitive function than those who were not. However, the same study also found that women are less likely than men to receive DMT treatment. Dive further into the findings with Dr. Andrew Wilner and Dr. Victoria Leavitt, Assistant Professor of Neuropsychology at Columbia University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Arnaud Bourdin, MD, PhD
It’s only been a recent discovery that mucus plugging may be present and persistent in chronic severe asthma.1 In fact, studies have shown that mucus plugs may drive some lung function deficits in severe asthma.1 Given this recent finding, Dr Charles Turck speaks with Professor Arnaud Bourdin about the clinical significance and pathogenesis of mucus plugging in severe asthma. Professor Bourdin is Head of Pulmonology at Arnaud de Villeneuve Hospital in Montpellier, France.
Reference:
- Dunican EM, Watchorn DC, Fahy JV. Ann Am Thorac Soc. 2018;15(Suppl 3):S184-S191. doi:10.1513/AnnalsATS.201807-485AW
©2024 Amgen and AstraZeneca. All rights reserved. US-86740 Last Updated 3/24
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Brian Iacoviello, MD
Since the thinking part of depression may involve getting stuck on the sad or the negative thoughts, there is a need to focus on not just cognitive control for information but for emotional information processing.1 And that fits with the picture that we get from brain imaging research that shows hyperactivity in the emotion-processing region of the brain and a quieting-down of the cognitive control region of the brain when people are depressed.1 To take a deep dive, join Dr. Brian Iacoviello, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.
Reference
- Iacoviello BM, Wu G, Alvarez E, et al. Cognitive-emotional training as an intervention for major depressive disorder. Depress Anxiety. 2014;31(8):699-706.
January 2024 US.UNB.X.23.00076
Guest: Aderonke Pederson, MD
Major depressive disorder is a mental health condition that affects millions of Americans,1 and for the past several decades, treatment has consisted mainly of antidepressant therapy and psychotherapy.2,3 However, many patients still don't achieve their treatment goals and there are many potential barriers to accessing treatment. Learn more about these unmet needs in major depressive disorder care that underscore the importance of finding new treatment approaches with Dr. Aderonke Pederson, Assistant Professor of Psychiatry at Harvard Medical School.
References:
- National Institute of Mental Health. Major depression. National Institute of Mental Health. July 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/statistics/major-depression
- National Institute of Mental Health. Depression. National Institute of Mental Health. September 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/topics/depression
- American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. American Psychiatric Association Publishing. 2010. Accessed November 10, 2023. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
January 2024 US.UNB.X.23.00150
Host: Jennifer Caudle, DO
Guest: Manpreet Mundi, MD
Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there’s an urgency to manage patients symptoms, and one option that’s been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota.
All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé
Guest: Jai Radhakrishnan, MD
The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York.
References:
- Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501
- Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000
- Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092
319698 12/23
Guest: Mark Haas, MD
Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles.
References:
- Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02
- Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254
319698 12/23
Guest: Richard Lafayette, MD, FACP
Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.1 That’s why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California.
References:
- Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004
319698 12/23
Guest: Stephen Greene, MD
One of the most important things we know about heart failure is that it doesn’t affect everyone equally, especially when you consider heart failure with reduced ejection fraction versus preserved ejection fraction. Dive into the complex pathophysiology and pathoetiology surrounding heart failure and how it differs when ejection fraction is reduced versus when it’s preserved with Dr. Stephen Greene, an advanced heart failure specialist at Duke Heart Transplant Clinic and a cardiologist at Duke Cardiology Clinic in Durham, North Carolina.
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
SC-US-75207 6/23
Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
Approximately 6.2 million adults in the US have heart failure (hf), and this number is projected to grow to more than 8 million by 2030. Knowing this alarming statistic, what do we need to know about the clinical characteristics of hf? Take a deep dive with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation.
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
SC-US-75207 3/23
Guest: Pamela Kushner, MD, FAAFP
The Cardio-Renal-Metabolic (CRM) systems are physiologically interconnected, and each one relies on energy homeostasis to
function properly. So why is it important for clinicians to understand the CRM continuum to identify and assess comorbidities in order to effectively treat patients with heart failure? Dive into this episode with Dr. Pam Kushner, Clinical Professor at the University of California at Irvine, a Clinical Trialist, past Chair of the American Academy of Family Physicians Drugs and Devices Committee, and a Family Medicine Doctor with a private practice in Long Beach, California.
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
SC-US-75207 3/23
Guest: Stephen Greene, MD
In 2022, the American Heart Association, American College of Cardiology, and Heart Failure Society of America created a joint guideline for the management of heart failure. Explore what the recommendations say and how they can help improve patient outcomes with Dr. Stephen Greene, an advanced heart failure specialist at Duke Heart Transplant Clinic and a cardiologist at Duke Cardiology Clinic in Durham, North Carolina.
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
SC-US-75207 6/23
Guest: Pamela Kushner, MD, FAAFP
Clinicians may agree that several challenges exist in diagnosing heart failure because patients may present with nonspecific symptoms or may have comorbidities. So what factors are important to evaluate when detecting and diagnosing heart failure in patients? Join Dr. Pam Kushner, clinical professor at the University of California at Irvine, as she walks us through the answer to this and more.
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
SC-US-75207 3/23
Guest: Nancy M. Albert, PhD, CCNS, CHFN, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN
There are 4 stages of heart failure, ranging from being at risk for heart failure to having an advanced condition. So what key insights should we know about the ACC/AHA stages of heart failure and the NYHA heart failure functional classifications? Discover more with Dr. Nancy Albert, associate chief nursing officer for the Office of Nursing Research and Innovation.
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.
SC-US-75207 3/23
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Amy Sehnert, MD
With the FDA’s approval of CAMZYOS® (mavacamten), the first and only cardiac myosin inhibitor for symptomatic New York Heart Association (NYHA) class II-III adult patients, healthcare professionals and patients now have another treatment option that targets HCM at the source. Learn more about the clinical trial data that supported the FDA approval, and how healthcare professionals can prescribe CAMZYOS from Dr. Amy Sehnert, Vice President and Head of Cardiomyopathy and Heart Failure Clinical Development at Bristol Myers Squibb.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kalpesh Thakkar, MD, MSCR
Cow’s milk protein allergy is the most common food allergy in infants. And overall, it’s important to know that in general, the incidence of allergy is increasing worldwide. To take a deep dive, join Dr. Charles Turck as he speaks with Dr. Kalpesh Thakkar, Pediatric Gastroenterologist at Memorial Hermann Medical Group in Sugarland, Texas.
All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé
Host: Jennifer Caudle, DO
Guest: Katherine Bennett, MPH, RD, CLEC
Caregivers and children often face challenges when trying to find a formula that’s well-tolerated, and the burden of feeding intolerance extends to the healthcare system as well. Find out how blenderized whole food tube feeding whole food tube feeding formulas like Compleat Organic Blends can help address those challenges and benefit pediatric patients with Dr. Jennifer Caudle and Ms. Katherine Bennett, a registered dietitian at the Children’s Hospital of Orange County in California.
All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé
Host: Sana Raoof, MD, PhD
Guest: Candace T. Westgate, DO, MPH, FACOG
Guest: Mylynda Massart, MD, PhD
The last five years have seen exciting progress with liquid biopsy tests, with one of them being a screening tool for multi-cancer early detection that looks for methylation patterns that can detect more cancers earlier, even before symptoms appear.1,2 Learn how you can incorporate this screening tool into clinical practice with Drs. Sana Raoof, Candace Westgate, and Mylynda Massart. Dr. Raoof is a physician scientist at Memorial Sloan Kettering Cancer Center, Dr. Westgate is the Medical Director of the AHEAD Program and Chief of Staff at Adventist Health Saint Helena in Northern California, and Dr. Massart is the Founder and Director of the UPMC’s Primary Care Precision Medicine Center.
References:
- Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501
- Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011
Host: Jennifer Caudle, DO
Guest: Sana Raoof, MD, PhD
There’s a multi-cancer early detection test available that uses a targeted methylation, next-generation sequencing-based assay to detect and analyze cell-free DNA in the bloodstream, deploy machine learning to detect a cancer signal, and predict the likely origin of the signal.2 Explore the science behind this advancement that provides the highest specificity of any cancer screening tool1 with Dr. Jennifer Caudle and Dr. Sana Raoof, physician scientist at Memorial Sloan Kettering Cancer Center.
References:
- Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel). 2021;13(14):3501. Published 2021 Jul 13. doi:10.3390/cancers13143501
- Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi:10.1016/j.annonc.2020.02.011
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jerome Goldschmidt, MD
Despite the potential benefits of biosimilars, such as decreased costs for patients, healthcare systems, and payers,1,2 their uptake in U.S. clinical practice has lagged behind that of the E.U.2 That’s why Dr. Jerome Goldschmidt joins Dr. Charles Turck to address common misconceptions surrounding biosimilars and examine key points in their development, manufacturing, and approval process. Dr. Goldschmidt is a medical oncology specialist practicing at Blue Ridge Cancer Care, and he’s also affiliated with the U.S. Oncology Network in Blacksburg, Virginia.
References:
1. IQVIA. Biosimilars in the United States 2023–2027: Competition, Savings, and Sustainability. 2023. Accessed June 20, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2023-2027
2. Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi:10.1016/j.semarthrit.2021.11.009
©2023 Amgen Inc. All rights reserved. USA-CBU-81658 8/23
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joseph F. Goldberg, MD, MS
Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.
August 2023 US.UNB.X.23.00071
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jonathan Silverberg, MD, PhD, MPH
Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.
References:
- Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
- Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
- Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
- De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.
©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23
Host: Joyce Riley
Guest: Lance Sloan, MD
Pneumococcal vaccination isn’t restricted to a specific season. Patients can get vaccinated with Prevnar 20 at any time. Clinicians can help their patients better understand the importance of pneumococcal vaccination. Join Joyce Riley as she gets expert insights from Dr. Lance Sloan, Endocrinologist, Nephrologist, and Metabolist in Lufkin, Texas.
Continuing medical education credits are not available for this program.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gil Melmed, MD, MS
The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program.
References:
-
US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/135612/download
-
US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/82647/download
©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23
Host: Jennifer Caudle, DO
Guest: Jeran Wadlow
Guest: Josh Elmassian, MBA
Allergan Medical Institute® has taken a personalized approach to training HCPs in medical aesthetics with the launch of AMI Online. Discover multiple online courses spanning the Allergan Aesthetics portfolio, including content on JUVÉDERM® VOLUX® XC. Experience how AMI Online’s evidence-based and progressive training curricula can educate and empower the aesthetics community. Join Dr Jennifer Caudle as she speaks with Jeran Wadlow, Associate Director, Digital at Allergan Medical Institute® in Irvine, California, and Josh Elmassian, Director of JUVÉDERM® US Commercial Business and Marketing at Allergan Aesthetics, in Irvine, California.
© 2023 AbbVie. All rights reserved.
PRT162857 06/23
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Mark Pennesi, MD, PhD
Approximately 165,700 people in the United States are affected by inherited retinal diseases (IRDs) and treatment options for these conditions are limited. So what role does genetic testing play in the patient journey of people living with IRDs? Join Dr. Charles Turck as he dives into this topic with Dr. Mark Pennesi, Professor of Ophthalmology and an IRD specialist affiliated with the Casey Eye Institute at the Oregon Health and Science University School of Medicine.
©Janssen Pharmaceuticals, Inc. 2023 05/23 cp-367503v1
Host: Ethan Craig, MD, MHS
Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP
Appealing treatment options for patients with SpA might be right around the corner. So why do we need further imaging modalities and what do they have to offer? To give us a peek into the future, Dr. Ethan Craig is joined by Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
How can we overcome diagnostic challenges and improve awareness for Still’s disease? Dr. Jason Liebowitz is joined by Dr. Bella Mehta from Cornell Medical College to explore the diagnosis landscape for this disease.
Dr. Liebowitz and Dr. Mehta are Novartis consultants.
10/22
Host: Ethan Craig, MD, MHS
Guest: Catherine J. Bakewell, MD
Disease activity in patients with spondyloarthritis (SpA) may be challenging to assess. So when should ultrasound and MRI be used to support clinical assessment? To provide us with more insights into this topic, Dr. Ethan Craig is joined by Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
Joining Dr. Ethan Craig to explore the role of patient-reported outcomes and discuss possible obstacles in disease monitoring is Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.
Host: Ethan Craig, MD, MHS
Guest: Walter Maksymowych, MB ChB, FRCP(C), FACP
Over the last 20 year or so, magnetic resonance imaging (MRI) has changed how we evaluate axial spondyloarthritis (axSpA). But with a concerning rate of false-positive MRIs in recent data, it’s time to review where the field stands now, and update what the role of MRI seems to be in the diagnosis of spondyloarthritis (SpA). Join Dr. Ethan Craig in this discussion with an expert in SpA imaging, Dr. Maksymowych, Professor of Medicine at the University of Alberta and Chief Medical Officer of CARE Arthritis.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 03/23
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
While Sjögren’s disease may be challenging to diagnose, imaging developments may improve the way we detect this disease.
To learn more, Dr. Ethan Craig is joined by Dr. Sara S. McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Ethan Craig, MD, MHS
Guest: Catherine J. Bakewell, MD
Diagnosing patients with peripheral spondyloarthritis (pSpA) can often be challenging, particularly when differentiating it from other causes of inflammatory and non-inflammatory arthritis. So what is the role of ultrasound when diagnosing pSpA in patients? Join Dr. Ethan Craig as he guides this discussion with Dr. Catherine Bakewell, Rheumatologist at Intermountain Healthcare in Salt Lake City, Utah.
Dr. Craig and Dr. Bakewell are Novartis Consultants.
269162 3/23
Guest: Shibeshih Belachew, MD PhD
Host: Charles Turck, PharmD, BCPS, BCCCP
Technology is advancing exponentially, and this has been more evident than ever in the field of medicine. In fact, biotech and pharmaceutical companies are bringing biology and technology together to better meet patient needs across a range of specialties. So what are the latest research and initiatives in digital health that are working towards a future of more personalized medicine for patients with multiple sclerosis (MS)? Joining Dr. Turck to share insights on digital health innovations in MS care is Dr. Shibeshih Belachew, Head of Science at Biogen Digital Health.
© 2023 Biogen. All rights reserved.
Host: Jennifer Caudle, DO
Guest: Stefanie Cribb, PharmD
Guest: Ryan Haumschild, PharmD
Guest: Jennifer Rubino
Guest: Ira Steinberg, MD
There’s been a lot of focus recently on biosimilars and their potential role in evolving the healthcare system. We're digging in deeper to understand what makes biosimilars so exciting. Joining Dr. Jennifer Caudle to discuss the biosimilar approval process and the important commitment supporting healthcare providers and patients in their adoption is a panel of experts: Dr. Stefanie Cribb, Dr. Ira Steinberg, and Ms. Jennifer Rubin from Coherus Biosciences and Dr. Ryan Haumschild from the Emory Healthcare and Winship Cancer Institute.
© 2022 Coherus BioSciences
C1122-COH-P829
Host: Marshall Miller
This episode of Rub Some Dirt in It is getting curiouser and curiouser. See if you can solve these two cases before host Marshall Miller reveals the rare and unexpected diagnoses.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamy Ard, MD
Guest: Michelle I. Cardel, PhD, MS, RD
Addressing obesity may be a key component of diabetes management, so integrating strategies to manage obesity may improve diabetes care. To better understand this, Dr. Jamy Ard and Dr. Michelle Cardel dive into the impact of evidence-based lifestyle interventions for people living with diabetes.
WW Logo and Weight Watchers are the trademarks of
WW International, Inc. and are used with permission.
Host: Jason Liebowitz, MD
Guest: Bella Mehta, MBBS, MS, MD
Polygenic autoinflammatory diseases can present in several ways, such as in still’s disease and systemic juvenile idiopathic arthritis. To share key insights on these diseases, Dr. Jason Liebowitz is joined by Dr. Bella Mehta from Cornell Medical College.
Dr. Liebowitz and Dr. Mehta are Novartis consultants.
10/22
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
From therapeutic options to potential outcomes, what factors should we consider when escalating treatment for patients with axial spondyloarthritis? Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center to dive into these key considerations.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
Sjogren's disease can be challenging to diagnose given that it can manifest in several different ways. How can we overcome this obstacle?
To share insights on combating diagnostic challenges, Dr. Ethan Craig is joined by Dr. Sara McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Counseling your patients about their risk of shingles—and encouraging them to get vaccinated—can help better protect them. But how do we do that? To answer this question, Dr. Christopher Altman discusses the risk of shingles with Dr. Jennifer Caudle.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Shingles can impact many of our patients 50 years and older, which is why we need to talk to them about their risk. To take a look at counselling strategies, Dr. Jennifer Caudle is joined by Dr. Christopher Altman, Director of Immunization & Clinical Programs.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Joining Dr. Jennifer Caudle to discuss how to talk to vaccine-hesitant patients about shingles vaccination and share insights is Dr. Christopher Altman, Director of Immunization and Clinical programs.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Joining Dr. Jennifer Caudle to explore how we should approach vaccine hesitancy and address concerns about cost and time constraints for shingles vaccination is Dr. Christopher Altman, Director of Immunization and Clinical Programs.
Sponsored by GSK
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
How can we improve rates for shingles vaccination across all ethnicities? To find out how, Dr. Jennifer Caudle is joined by Dr. Christopher Altman to explore discrepancies in vaccination rates.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: William Lumry, MD
Hereditary angioedema (HAE) is a rare, genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.1 These swelling attacks can be both painful and debilitating, which is why prevention is so important.1 So what are the treatment options available that can help prevent HAE attacks? Joining Dr. Jennifer Caudle to discuss the importance of long-term prevention for HAE and the role of the treatment option TAKHZYRO (lanadelumab-flyo) is Dr. William Lumry, Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School.
IndicationTAKHZYRO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
Important Safety InformationHypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in …
Guest: Dr. Timothy Craig
Hereditary angioedema (HAE) is a rare genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.2 The unpredictability of these attacks is a significant burden on patients.3 Fortunately, preventive treatments like TAKHZYRO® (lanadelumab-flyo) can help reduce the frequency and severity of HAE attacks.1 Here to share key information and data on this treatment option is Dr. Timothy Craig, Professor of Pulmonary, Allergy, and Critical Care Medicine at Pennsylvania State University.
IndicationTAKHZYRO® (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
Important Safety InformationHypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.
No data are …
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To figure out how to improve the detection of fibromyalgia and axial spondyloarthritis, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
11/22
Host: Bradley Torphy, MD
Learn more about the efficacy and other clinical data for this preventive migraine treatment option. Dr. Brad Torphy highlights clinical data on this treatment option.
Host: Wade Cooper, DO
For patients with chronic or episodic migraine, what treatment options should we consider? To help answer that question, Dr. Wade Cooper discusses a treatment option for migraine.
Host: Jennifer Caudle, DO
Guest: Majed Refaai, MD
While VKA-related GI bleeds are common, clinicians need to be aware of the severity of the bleed, especially in cases of hemodynamic instability. To get a better understanding of the impact of this severity, Dr. Majed Refaai from the University of Rochester Medical Center shares insights on these life-threatening bleeds.
Host: Ethan Craig, MD, MHS
Guest: Sara S. McCoy, MD, PhD
Because Sjogren's disease has no calculable disease activity scores or established guidelines, how do clinicians monitor disease activity?
Dr. Ethan Craig is joined by Dr. Sara S. McCoy, MD, PhD who runs the Sjögren’s Clinic at the University of Wisconsin to discuss activity monitoring for Sjögren’s disease.
Dr. Craig and Dr. McCoy are Novartis consultants.
247548 11/22
Guest: Narjust Duma, MD
Guest: David J. Feller-Kopman, MD
Guest: Bruce E. Johnson, MD
Guest: Razelle Kurzrock, MD, FACP
Guest: Ignacio Wistuba, MD
Lung cancer incidence is decreasing due in part to reduced smoking rates, and new trends are emerging as things change. But despite these advancements, some challenges remain to be solved. Explore those challenges and key strategies for overcoming them in this four-part series.
PP-US-8201a-1520 12/22
Guest: Andrew Menzies-Gow, PhD
Host: Charles Turck, PharmD, BCPS, BCCCP
Is now the time to shift the asthma management paradigm to prioritize remission as our goal? Dr. Charles Turck is joined by Professor Andrew Menzies-Gow, Director of the Lung Division and Deputy Medical Director at the Royal Brompton and Harefield Hospitals, London, UK, to discuss remission as a goal for patients with asthma. Together, they review a recently published expert consensus framework for asthma remission and discuss whether targeting remission could lead to better outcomes for patients.
At the time of recording, Professor Menzies-Gow provided services to AstraZeneca as an External Expert; Professor Menzies-Gow is now a permanent employee at AstraZeneca.
©2022 Amgen and AstraZeneca. All rights reserved. US-69837 Last Updated 12/22
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Different domains of psoriatic arthritis can look different in each of our patients. How should that factor into our evaluation and treatment approach for this disease? Dr. Jason Liebowitz sits down with Dr. Laura Coates, an Associate Professor at Oxford University, to explore a domain-based approach to care.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Hunter, MD
It’s important to recognize that older adults are more susceptible to influenza infection—as well as increased severity of infection—than younger, healthier populations.1 Fortunately, there are vaccines available that can help prevent influenza in this aging population. But do the relative benefits and harms of higher-dose and adjuvanted vaccines, compared with one another and with other influenza vaccines, favor the use of any one or more of these vaccines over other age-appropriate options for people 65 and older?2 That's the exact question the CDC’s Advisory Committee on Immunization Practices (ACIP) sought to answer and what Dr. Charles Turck discusses with Dr. Paul Hunter, Associate Professor in the Department of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health.
References:
1. Centers for Disease Control and Prevention. Fly & People 65 Years and Older. Accessed August 16, 2022. https://www.cdc.gov/flu/highrisk/65over.htm.
2. National Center for Immunization & Respiratory Diseases. Advisory Committee on Influenza Practices. Influenza Vaccines for Older Adults: GRADE Summary. Accessed August 16, 2022.
USA-FLUD-22-0056 December 2022
Host: Ethan Craig, MD, MHS
Guest: Dr. Lianne Gensler, MD
To help us understand how axial spondyloarthritis (axSpA) and inflammatory back pain (IBP) differ, Dr. Ethan Craig is joined by Dr. Lianne Gensler from the UCSF Spondylitis Clinic at the University of California San Francisco Medical Center.
Dr. Craig and Dr. Gensler are Novartis consultants.
249165 11/22
HPV testing plays an important role in cervical cancer screening, but not every patient whose HPV-positive will develop cervical cancer. One option that can help us identify which HPV-positive patients are truly at risk is CINtec PLUS Cytology, an immunohistochemistry test that simultaneously detects p16 and Ki67 biomarker proteins. Learn more about how this dual staining technique works in this video.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.
Host: Jason Liebowitz, MD
Guest: Laura Coates, MBChB, MRCP, PhD
Given that recommendations for treatment are constantly evolving, how should we adjust our therapeutic approach to provide optimal care? To answer that question, Dr. Jason Liebowitz is joined by Dr. Laura Coates, an Associate Professor at Oxford University.
Dr. Liebowitz and Dr. Coates are Novartis consultants.
245473 11/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: David Mohr, PhD
In addition to potentially improving access to mental health care, digital tools have also been shown to improve symptoms in many types of mental illness1 and can serve as an adjunct to psychotherapy or pharmacotherapy. Despite this, these tools have not yet been widely adopted in the United States. So what are some strategies we can use to implement these tools and develop an improved framework? Joining Dr. Charles Turck to discuss mental health treatments and their application in clinical practice is Dr. David Mohr, a Professor in the Department of Preventive Medicine at Northwestern University Feinberg School of Medicine in Chicago.
Reference:
- Mohr DC, Azocar F, Bertagnolli A, et al. Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment. Psychiatr Serv. 2021;72(6):677-683.
December 2022 US.UNB.X.22.00074
Guest: John Anderson, MD
HAE is a rare, autosomal dominant genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.1 There are approximately 6,000 patients living with HAE in the U.S. alone,2 and it’s not uncommon for patients to go undiagnosed for years after they start experiencing symptoms.1 Since early diagnosis is vital to creating a management plan that meets each patient’s individual needs,2 Dr. John Anderson is here to share key information on how we can better diagnose HAE in our patients.
References:
- Banerji A. Hereditary Angioedema: Classification, Pathogenesis, and Diagnosis. Allergy Asthma Proc. 2011;32:403–407.
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.
©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
US-NON-7744v1.0 10/22
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
As advancements in imaging continue to emerge, what does that mean for the management of gout, calcium pyrophosphate deposition, and crystalline arthritis? To answer this question, Dr. Jason Liebowitz is joined by Dr. Sara Tedsechi from Harvard Medical School.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants.
10/22
Guest: Professor Christopher Brightling, PhD, FMedSci
Guest: Professor Bruce Levy, MD
Host: Charles Turck, PharmD, BCPS, BCCCP
For an asthma patient with active airway hyperresponsiveness, what kind of role do airway structural changes and mast cells play? And why is airway hyperresponsiveness so important? Professor Chris Brightling and Professor Bruce Levy share their clinical perspectives on airway hyperresponsiveness.
©2022 Amgen and AstraZeneca. All rights reserved. US-69836 Last Updated 10/22
Host: Jennifer Caudle, DO
Guest: Joseph Aloi, MD
The rate of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) continues to rise. What can we do to slow this progression of CKD? Dr. Joseph Aloi from the Wake Forest School of Medicine explores this growing epidemic and discusses how a new tool may aid in early risk assessment of early stage 1-3b CKD.
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
So how and when should we escalate or change treatments in patients with psoriatic arthritis (PsA)? To answer this question, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Guest: Marc Riedl, MD, MS
Prior to 2008, there were limited approved treatment options for hereditary angioedema (HAE) available in the United States, but today, there are several medications approved by the U.S. Food and Drug Administration for preventing and treating HAE attacks.1 In light of the number of therapies that have been approved in recent years and continued clinical advancements in HAE research, what do we need to consider when discussing these treatment options with our patients? Here to share those key considerations and important information on the HAE treatment landscape is Dr. Marc Riedl.
References:
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3.
©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
What are some way we can overcome the challenges that come with monitoring response to therapy for patients with psoriatic arthritis (PsA)? Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania to discuss the importance of monitoring and share strategies.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Jason Liebowitz, MD
Guest: Sara Tedeschi, PA
What do we need to know about the epidemiology and pathogenesis of calcium pyrophosphate deposition? Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School to share key insights on CPPD.
Dr. Liebowitz and Dr. Tedeschi are Novartis consultants
10/22 236268
Host: Jennifer Caudle, DO
Guest: Sandra P. Reyna, MD
Spinal muscular atrophy (SMA) is a challenging rare disease that requires a diagnosis and access to treatment as early as possible. To help us understand the importance of early treatment, Dr. Sandra Reyna from Novartis Gene Therapies shares key considerations for optimizing outcomes and gives us some insight into available SMA treatment options, focusing on the gene therapy ZOLGENSMA.
© 2022 Novartis Gene Therapies, Inc.
US-ZOL-22-0129 08/22
Host: Matt Birnholz, MD
Guest: David Canaday, MD
As we age, our immune system becomes weaker and is therefore unable to ward off infection as easily as in our younger years.1 This is particularly troublesome during flu season. In fact, the CDC’s Advisory Committee on Immunization Practices (ACIP) recently looked at flu vaccine data for adults aged 65 years and older, and they now recommend that this age group preferentially receive higher dose or adjuvanted vaccines over standard dose unadjuvanted vaccines when available.2 So what was the data that led to these updated recommendations? Joining Dr. Matt Birnholz to share those key findings and the role of adjuvanted vaccines like FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) in preventing influenza in older adults is Dr. David Canaday, Professor in the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University in Cleveland.
Avoid use in patients who have experienced any severe allergic reactions to any component of the vaccine. For more risk information please see below or consult the Full US Prescribing Information for FLUAD® QUADRIVALENT here.
References:
1. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659-666.
2. Centers for Disease Control and Prevention. Past seasons estimated influenza disease …
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie, MD, MSCE
For patients with oligoarticular arthritis, how can imaging features help us distinguish psoriatic arthritis from other inflammatory processes? Joining Dr. Ethan Craig to answer that question is Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What does the therapeutic landscape look like for patients with giant cell arthritis (GCA)? Joining Dr. Anisha Dua to highlight the need for more targeted therapies is Dr. Mike Putman from the Medical College of Wisconsin.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Matthew N. Brams, MD
Since the use of digital tools in psychiatry and mental health treatment is already a reality, it’s important to know how to find the digital tool that best suits your and your patients’ needs and—perhaps even more importantly—how to encourage patients to use the tool. That’s why Dr. Charles Turck speaks with Dr. Matthew Brams, who shares the benefits of digital tools, the data he’s able to gain from them, how he talks to patients, and more.
July 2022 US.UNB.X.22.00009
Host: Jennifer Caudle, DO
Guest: Daniel R. Karlin, MD, MA
Digital tools have emerged as one of the newest therapeutic modalities for behavior modification in several chronic psychiatric diseases,1 such as major depressive disorder, chronic insomnia, and substance use disorders. But what exactly are these digital tools, and what does their use look like in practice? Joining Dr. Jennifer Caudle to answer those and other key questions regarding the use of digital tools in psychiatry is Dr. Daniel Karlin, Assistant Professor of Psychiatry at Tufts University in Boston and Chief Medical Officer at MindMed in New York City.
References:
- Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med. 2020;3:159.
August 2022 US.UNB.X.22.00018
Host: Ethan Craig, MD, MHS
Guest: Alexis Ogdie-Beatty, MD, MSCE
How does preclinical psoriatic arthritis (PsA) progress into chronic PsA? To dive into this path of progression, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.
Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.
221663 7/22
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
What are some imaging factors we should consider when monitoring giant cell arthritis (GCA) and the medication prescribed for it? Dr. Anisha Dua is joined by Dr. Mike Putman to explore these factors.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The risk of developing cancer may be higher in patients with spondyloarthritis, or SpA for short.1-6 What do we need to know about the risk of cancer, as well as other malignancies in these patients? Dr. Anisha Dua joins Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to explore malignancies in SpA.
Dr. Dua and Dr. Husni are Novartis consultants.
- Deng C, Li W, Fei Y, Li Y, Zhang F. Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis. Sci Rep. 2016;6:1-6.
- Gross R, Schwartzman-Morris J, Krathen M, et al. A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472-1481.
- Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatology. 2016;152(3):282-290.
- Moon H-I, Chang H-J, Kim J-E, Ko H-Y, Ann S-H, Min C-K. The association between multiple myeloma and ankylosing spondylitis: a report of two cases. Korean J Hematol. 2009;44(3):182-187.
- Chang CC, Chang CW, Nguyen PAA, et al. Ankylosing spondylitis and the risk of cancer. Oncol Lett. 2017;14(2):1315-1322.
- Karmacharya P, Shahukhal …
Host: Anisha Dua, MD, MPH
Guest: Michael Putman, MD, MSci
With several guidelines available—what imaging considerations should we keep in mind when it comes to diagnosing giant cell arthritis (GCA)? Joining Dr. Anisha Dua to walk us through the guidelines and make recommendations is Dr. Mike Putman.
Dr. Dua and Dr. Putman are Novartis consultants.
199849 6/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
The estimates of prevalence of depression across the axial spondyloarthritis spectrum ranges from 11% to 64%. How we can help these patients manage their mental health? To find out more, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
Zhao SS, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20(1):1-9.
196466 6/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve diversity in the rheumatology workforce? Joining Dr. Anisha Dua to explore underrepresentation in the workforce are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Guest: Elaine Husni, MD, MPH
Host: Anisha Dua, MD, MPH
Physical activity has shown to have many benefits for patients with spondyloarthritis, or SpA for short. What kind of role does it have in the treatment of these patients? To answer this question, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Dr. Dua and Dr. Husni are Novartis consultants.
O’Dwyer T, O’Shea F, Wilson F. Physical activity in spondyloarthritis: a systematic review. Rheumatol Int. 2015;35(3):393-404.
196466 6/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
What are some of the social determinants that can impact patient outcomes? Joining Dr. Anisha Dua to share strategies to improve these inequities are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Shared treatment decisions can help guide patient care—but how can we implement them in our practice? Drs. Jason Liebowitz and Michael Putman share tips and strategies to implement shared decision-making (SDM) in rheumatology.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Elaine Husni, MD, MPH
Patients with spondyloarthritis, or SpA for short, can be at an increased cardiovascular risk.1,2 To learn how we can better understand and manage this risk, Dr. Anisha Dua is joined by Dr. Elaine Husni from the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. Dua and Dr. Husni are Novartis consultants.
- Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatol (United Kingdom). 2020;59:iv47-iv57.
- Papagoras C, Markatseli TE, Saougou I, et al. Cardiovascular risk profile in patients with spondyloarthritis. Jt Bone Spine. 2014;81(1):57-63.
196466 6/22
Host: Jason Liebowitz, MD
Guest: Michael Putman, MD, MSci
Social media is often used as a tool to network and connect to people around the world—but can rheumatologists use it to connect with their patients? Drs. Jason Liebowitz and Michael Putman share how rheumatologists can use it to improve care.
Dr. Liebowitz and Dr. Putman are Novartis consultants.
194889 4/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
What are some ways we can improve diversity in our workforce? Joining Dr. Anisha Dua to share how clinicians can make the workforce more inclusive are Dr. Grace Wright and Dr. Irene Blanco.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Jennifer Caudle, DO
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Guest: Gary Marshall, MD
It's well understood that annual vaccination is the best way to help reduce the high burden associated with influenza. And while most influenza vaccines available in the United States are produced in eggs, this presents some inherent challenges, which can lead to reduced vaccine effectiveness. Fortunately, alternative production processes can help us overcome those challenges, and to learn more, Dr. Jennifer Caudle speaks with Dr. Wendy Wright and Dr. Gary Marshall.
USA-CRP-22-0018 May 2022
HER2 (ERBB2) mutations may increase receptor internalization and lead to hyperactive downstream signaling, uncontrolled cell growth, and tumorigenesis. Learn more about how HER2 mutations affect several types of cancer, including non-small cell lung cancer (NSCLC).
Intended for US Healthcare Professions only
©2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1332 06/22
Host: Anisha Dua, MD, MPH
Guest: Grace C Wright, MD, PhD
Guest: Irene Blanco, MD, MS
How can we improve representation in rheumatology clinical trials? To share strategies, Dr. Anisha Dua joins Dr. Grace Wright and Dr. Irene Blanco to discuss diversity in clinical trials.
Drs. Dua, Blanco, and Wright are Novartis consultants.
194889 4/22
Host: Barry A. Singer, MD
Patients living with MS can experience hidden or invisible symptoms that may not be apparent to others but can affect how they feel and function. In this podcast, Dr. Barry Singer, the Director at the Multiple Sclerosis Center for Innovations in Care, and Rosario, a patient who has been living with MS for 10 years, discuss their clinical and personal experiences with MS, and the impact that MS can have on a patient's QoL.
In the 2-year AFFIRM pivotal trial: Relapsing MS patients received 300 mg TYSABRI every 28 days (n=627) or placebo (n=315). Patients with PPMS, SPMS, and PRMS were excluded.2,3
83% of patients taking TYSABRI had no sustained disability progression for 12 weeks vs 71% with placebo (primary endpoint: 17% vs 29%; p<0.001).2,3
Dr. Singer reviews the results of a recent publication from Hersh et al, which describes the effect of TYSABRI® (natalizumab) on various aspects of a patient’s QoL. In the study, 164 patients reported their experience after starting TYSABRI using a standard Quality of Life in Neurological Disorders (Neuro-QoL) assessment of 12 domains, which included anxiety, depression, positive affect and well-being, emotional and behavioral dyscontrol, stigma, cognitive function, sleep disturbance, fatigue, participation and satisfaction with social …
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Nichole Tanner, MD, MS, FCCP
Guest: Fabien Maldonado, MD, FCCP
Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.
Guest: Joel Neal, MD, PhD
Guest: Alexander Spira, MD, PhD, FACP
With the recent approvals of mobocertinib and amivantamab, we now have targeted therapies for EGFR exon 20 insertion–positive locally advanced or metastatic NSCLC, following progression on or after platinum-based chemotherapy. To learn more about mobocertinib, Dr. Joel Neal (Stanford) speaks with Dr. Alexander Spira (Virginia Cancer Specialists Research Institute) about the historical unmet need for this patient population, how mobocertinib is different from classical EGFR TKIs, and the clinical data that led to its FDA approval.
All trademarks are property of their respective owners.
Guest: Kenneth J. Moise Jr., MD
Host: Charles Turck, PharmD, BCPS, BCCCP
Hemolytic disease of the fetus/newborn (HDFN) may be rare, but it is important to recognize and diagnose the disease and ensure appropriate patient management since the consequences in cases that go undiagnosed or are poorly managed can be devastating. To help us gain a better understanding of maternal alloimmunization and the risk for HDFN in pregnancy, Dr. Charles Turck speaks with Dr. Kenneth Moise, Director of the Comprehensive Fetal Care Center in Texas.
© Janssen Pharmaceuticals, Inc. 2022 12/21 cp-272563v1
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Anjay Rastogi, MD, PhD
Defined as high potassium levels in the blood, hyperkalemia can be a life-threatening condition.1 Hyperkalemia is often associated with chronic kidney disease and can be silent or present itself with non-specific symptoms.1,2 However, there are challenges in managing hyperkalemia as a recurrent event.1,3 To help address these challenges, Dr Charles Turck discusses with Dr Anjay Rastogi, nephrologist and head of the CORE Kidney Program at UCLA, the burden of hyperkalemia and how potassium binders can help manage it.3,4 ©2022 AstraZeneca. All rights reserved. US-57356 Last Updated 2/22
Host: Jacqueline Nicholas, MD, MPH
Ever had a multiple sclerosis (MS) patient who needed to start a DMT? Listen to Dr. Jacqueline Nicholas, System Chief of Neuroimmunology and Director of MS Research at Ohio Health, and Kim, a patient who has been living with MS for seven years, share their experiences with the treatment decision process, including benefit-risk considerations, treatment goals, and patient preferences. They talk about the process for starting and continuing treatment with TYSABRI® (natalizumab) and how Biogen Support Services can help.
Please see Important Safety Information, including Boxed Warning for PML, below.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Carlos Jesus Acuña-Villaorduña, MD
What are some of the immunologic mechanisms that alter our ability to fight off a mycobacterium tuberculosis infection—and how does this affect our immunocompromised patients? To answer this question, Dr. Charles Turck meets with Dr. Carlos Acuña-Villaorduña from the Boston University School of Medicine to discuss new insights on TB infection and immunosuppression.
Host: Jane Mast, PA-C, MPAS, DMSc
Guest: Douglas DiRuggiero, DMSc, PA-C
Join podcast guest Doug DiRuggiero, PA, a certified physician assistant and the founding president of Georgia Dermatology Physician Assistant Society, and host Jane Mast, a Novartis Medical Director and certified physician assistant in a discussion focusing on the diagnosis and management of psoriasis in pediatric and adolescent patients.
During their discussion, they address the following topics:
- Important clinical features of psoriasis in children and adolescents and how they may differ from those in adult patients
- Communication strategies to use when talking to parents about their child’s psoriasis
- Psychosocial impact of psoriasis
- Approaches to management
This podcast is sponsored by Novartis Pharmaceuticals Corporation and the podcast guest is being compensated for his time.
© 2021 Novartis Pharmaceuticals Corporation
Guest: Eser Adiguzel, PhD (Novartis)
Guest: Randy Wong, MD (Novartis)
A common complication of diabetes is diabetic macular edema (DME). Of the 463 million people worldwide aged 29 to 79 years old living with diabetes, many will develop diabetic retinopathy at about a rate of 27 percent. And of those 27 percent, a smaller subset will develop DME.1,2 Given its high prevalence, it’s important to understand its pathophysiology, clinical features, challenges, and management approaches, which is why Drs. Eser Adiguzel and Randy Wong are here to share their insights on DME.
- International Diabetes Federation. Diabetes Atlas 9th Edition. 2019.
- Thomas RL, et al. Diabetes Res Clin Pract. 2019 Nov; 157:107840.
181534 2/22
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Diane M. Harper, M.D., M.P.H., M.S.
While HPV 16 causes nearly 60 percent of the cervical cancers, it’s only associated with about 20 percent of the NILM, ASCUS, and LSIL cytology diagnoses. This means that 80 percent of early screening abnormalities associated with types other than 16 are missed. So how can we better detect types beyond HPV types 16 and 18? Joining Dr. Charles Turck to discuss same-genotype persistence for high-risk HPV is Dr. Diane Harper.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Donald Middleton, MD
Influenza causes considerable morbidity and mortality in children. In fact, the CDC estimates that from the 2010-2011 season to the 2019-2020 season, seasonal flu-related hospitalizations among children younger than 5 years old have ranged from 7,000 to as high as 26,000 every year.1 This is a sobering reminder of the pivotal role vaccination plays in preventing influenza disease, and now, recent safety and immunogenicity data has led to the expanded age indication for the cell-based vaccine FLUCELVAX QUADRIVALENT. Explore that data and what this approval means for patients 6 months of age and older with Drs. Charles Turck and Donald Middleton.
- Centers for Disease Control and Prevention. Flu and young children. https://www.cdc.gov/flu/highrisk/children.htm. Accessed December 22, 2021
USA-QIVc-21-0169 December 2021
Host: Matt Birnholz, MD
Guest: Andrew Wang, MD
Although hypertrophic cardiomyopathy is the most common inherited heart disease, it is estimated that many patients remain undiagnosed. But why is that, what are the steps to help close the diagnostic gap, and what are the current management approaches for HCM? Joining Dr. Matt Birnholz to answer these questions and more is Dr. Andrew Wang, Vice Chief for Clinical Affairs for Duke University's Division of Cardiology and Director of the Duke Hypertrophic Cardiomyopathy Clinic.
Guest: S. Michelle Shiller, DO, AP/CP, MGP
Guest: John V. Heymach, MD, PhD
Exon 20 insertion mutations account for up to 10 percent of EGFR mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, EGFR mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.
All trademarks are the property of their respective owners.
Host: Linda Stein Gold, MD
Guest: Jonathan S. Weiss, MD
When assessing the burden of psoriasis, are you looking beyond the skin? Here to share their perspectives on the burden of psoriasis are Dr. Linda Stein Gold and Jonathan Weiss. Together, they’ll discuss the psychological impacts of psoriasis, how we can talk to patients, and more.
Host: Linda Stein Gold, MD
Guest: Jonathan S. Weiss, MD
Our understanding of the pathogenesis and pathophysiology of psoriasis continues to evolve, with one of the more recent pathways identified being the aryl hydrocarbon receptor. Here to share what we currently know about the role of the aryl hydrocarbon receptor in psoriasis are Dr. Linda Stein Gold and Jonathan Weiss.
Host: Linda Stein Gold, MD
Guest: Keri Holyoak, PA-C, MPH
When it comes to psoriasis, it’s important to not just treat the skin, but also the patient as a whole. That’s why Dr. Linda Stein Gold and Keri Holyoak are here to discuss the often-overlooked psychosocial burden of psoriasis and how we can talk to our patients about their mental health.
Host: Hector O. Chapa, MD, FACOG
Guest: Linda Ahn, MD, FACOG
Amid growing evidence that infection with high-risk HPV can increase the risk of cervical cancer, the American College of Obstetricians and Gynecologists, the American Society for Colposcopy and Cervical Pathology, and the American Cancer Society have all updated their guidelines to help identify patients at risk while reducing unnecessary invasive procedures and over-testing. Joining Dr. Hector Chapa to walk us through these guidelines is board-certified obstetrician/gynecologist Dr. Linda Ahn.
Guest: Norman E. Lepor, MD
Tune in to hear Dr. Norman Lepor from the UCLA Geffen School of Medicine discuss the role of LDL-C and comorbidities in atherosclerotic cardiovascular disease (ASCVD) risk assessment as well as the limitations of statin treatment.
10/21 121913
Guest: Rami Komrokji, MD
Guest: Natasha Johnson, MSN, APRN, AOCNP
Myelodysplastic syndromes (MDS) can require lifelong treatment.1 Learn how hematologist-oncologist Dr. Rami Komrokji and nurse practitioner Ms. Natasha Johnson approach their MDS protocol–from characterization, to diagnosis, to treatment. Together, they explain their process for scoring, transplants, and choosing a treatment regimen. They also share their experiences with INQOVI® (decitabine and cedazuridine), the only oral hypomethylating agent in the treatment of MDS, including chronic myelomonocytic leukemia.2
References: 1. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107. 2. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.
Guest: Vivian Shi, MD, FAAD
Atopic dermatitis is one of the most common chronic inflammatory skin diseases in America, especially among African American and Asian American patients. However, several factors contribute to the misdiagnosis and underdiagnosis of atopic dermatitis among these patients, which is why Dr. Vivian Shi is here to shed light on those factors as well as the key signs and symptoms of atopic dermatitis in patients with skin of color.
VERSION 1.0 | NOVEMBER 2021 | ABBV-US-00686-MC
Host: Jennifer Caudle, DO
Guest: Mark Socinski, MD
Dr. Mark Socinski from the AdventHealth Cancer Institute in Florida joins Dr. Jennifer Caudle to discuss a patient profile in the treatment of relapsed small cell lung cancer to help us better understand the burden of this disease and how to approach treating patients in the second-line setting with treatment options like ZEPZELCA.
Guest: Ashley Moncrief, RN, BSN
Guest: Natasha Johnson, MSN, APRN, AOCNP
Tune in to hear nurse practitioners Ms. Natasha Johnson and Ms. Ashley Moncrief discuss myelodysplastic syndromes (MDS), a rare type of blood cancer, and how it is classified and identified. Together, they share personal experiences from their practices and tips for conversations with MDS patients about their care.
© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0390
Guest: Azra Raza, MD
Guest: Rami Komrokji, MD
Listen to hematologist-oncologists Drs. Rami Komrokji and Azra Raza discuss myelodysplastic syndromes (MDS). Together, they explain the classification system for diagnosing this rare blood disorder and touch upon current events in the space and the impact on patients living with MDS.
© TAIHO ONCOLOGY 11/2021 INQ-PM-US-0384
Guest: Vivian Shi, MD, FAAD
Atopic dermatitis affects patients’ lives in a way that goes beyond just visible symptoms. In fact, many patients with atopic dermatitis also suffer from anxiety, depression, and attention deficit hyperactivity disorder. That’s why Dr. Vivian Shi is here to review available tools that can help us assess the severity of the visible and invisible impacts of atopic dermatitis.
VERSION 2.0 | DECEMBER 2021 | ABBV-US-00687-MC
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Manish Thapar, MD, AGAF, FAASLD, FACG
Acute hepatic porphyria (AHP) is a rare genetic condition characterized by severe, diffuse abdominal pain and a broad range of seemingly unrelated symptoms. AHP presents differently in each patient, with symptoms that mirror those of more common conditions, making it difficult to diagnose. Although AHP can be misleading, it can be easy to detect once you know what to look for. Joining Dr. Charles Turck to discuss AHP signs and symptoms and when a doctor should consider AHP in a patient is porphyria expert Dr. Manish Thapar, gastroenterologist and associate professor of medicine in Philadelphia.
©2021 Alnylam Pharmaceuticals, Inc. All Rights Reserved. AS1-USA-01069
Host: Jennifer Caudle, DO
Guest: Erik Munson, Ph.D
Mycoplasma genitalium (M. gen) is an STI that shares similar health consequences to chlamydia and gonorrhea. Further complicating this health threat is the fact that there’s been little guidance on how to manage this new pathogen until recently when the 2021 STI Treatment Guidelines were released. Joining Dr. Jennifer Caudle to talk about M. gen and why the guidelines recommend the use of nucleic acid amplification tests for the diagnosis of this pathogen is Dr. Erik Munson, an Assistant Professor of Clinical Laboratory Science at Marquette University.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Mark Blatter, MD
Despite their crucial role in preventing seasonal influenza, traditional influenza vaccines may not be providing as much protection as we thought, leading researchers to take a look at different methods of vaccine production, specifically cell-based flu vaccine production. Here with Dr. Charles Turck to discuss influenza prevention and the latest evidence supporting a cell-based vaccine option is Dr. Mark Blatter.
USA-QIVc-21-0146 November 2021
Host: Jennifer Caudle, DO
Guest: Melodie Young, MSN
Plaque psoriasis is canonically characterized by red, scaly, well demarcated plaques; however, the impact of this chronic systemic disease cannot be fully understood by the extent of skin involvement alone. Moderate psoriasis can have a large impact on patients due to factors such as involvement of special areas (such as the scalp) and persistent itching. Reaching a better understanding of these patients requires looking beyond skin involvement, assessing all aspects of disease, and considering patient perspectives.
Ms. Melodie Young, a Nurse Practitioner specialist of dermatology, joins Dr. Jennifer Caudle to give us deeper insight into this systemic disease, the potential impact on patients with moderate disease, and important aspects of psoriasis to consider in disease assessment.
USA-407-81472
Guest: Ann D. Bass, MD
Guest: Barry A. Singer, MD
Multiple sclerosis is a chronic inflammatory and neurodegenerative disease with a highly variable clinical course.1,2 Most patients who have relapsing-remitting multiple sclerosis (RRMS) will eventually transition to a secondary progressive course (SPMS).3 Patients with SPMS may live with significant impairment in physical and cognitive functions.4 Early identification of disease progression is important.2
Join Dr. Barry Singer from the MS Center for Innovations in Care at the Missouri Baptist Medical Center in St Louis, Missouri as well as Dr. Ann Bass from the Neurology Center of San Antonio in San Antonio, Texas as they share their real-world clinical perspectives on the management of patients with more progressed RMS, including those with aSPMS, and MAYZENT as a treatment option. Together, they will explore the following decision points:
- How to actively identify first signs of RMS progression
- A therapy for progressing RMS, including active SPMS
- What to consider when getting patients started on MAYZENT, a disease-modifying treatment
Host: Jason Freeman, MD, MBA
Guest: Scott Zamvil, MD, PhD
Our understanding of immunoglobins’ role in multiple sclerosis (MS) has evolved over the years. Joining Dr. Jason Freeman to share what we currently know about immunoglobins and immunology considerations for MS therapies and patient case scenarios is Dr. Scott Zamvil, Professor of Neurology and Faculty Member in the Program in Immunology at the University of California, San Francisco.
9/21 152858
Have you considered POMALYST® (pomalidomide) containing regimens for your appropriate patients with relapsed/refractory multiple myeloma who have received lenalidomide and a proteasome inhibitor? Tune in to hear key findings from clinical trials, including safety and efficacy data, and other important information regarding these treatment regimens.
Please see full Prescribing Information for POMALYST, including Boxed WARNINGS, and full Prescribing Information for EMPLICITI.
POMALYST and EMPLICITI Indications
POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
EMPLICITI® (elotuzumab) is indicated in combination with POMALYST and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
POMALYST + dexamethasone + daratumumab Indication
POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Information about POMALYST + dexamethasone + …
Host: John J. Russell, MD
Guest: Greg Berry, MD
We are at a time when COVID-19, respiratory syncytial virus, and the flu all pose serious risks. Quick and accurate diagnoses are vital to determining the correct patient pathway and minimizing viral spread. But what diagnostic challenges do we face, and how can we overcome them? Joining Dr. John Russell to discuss these respiratory testing challenges and Cepheid’s 4-in-1 respiratory test is Dr. Greg Berry, Associate Director of the Center for Advanced Laboratory Medicine at the Columbia University Irving Medical Center in New York.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Karen Keough, MD
Guest: Dawn S. Eliashiv, MD
Dr. Dawn Eliashiv of the University of California—Los Angeles and Dr. Karen Keough of the Child Neurology Consultants of Austin, Texas discuss using EPIDIOLEX® to treat patients 1 year of age or older with seizures associated with LGS, Dravet syndrome, or TSC.
Host: Stuart H. Isaacson, MD
Guest: Salima Brillman, MD
Guest: Sean C. Beinart, MD
Join Dr. Stuart Isaacson, a neurologist and movement disorder specialist, as he welcomes fellow neurologist and movement disorder specialist Dr. Salima Brillman and cardiologist Dr. Sean Beinart to discuss neurogenic orthostatic hypotension (nOH) causes, symptomatology, disease burden, and approaches to optimal management involving collaboration between neurology and cardiology specialists.
During their discussion, the following questions will be addressed:
- What is nOH and how is it diagnosed?
- What leads to symptoms of nOH?
- What are some common and less common symptoms of nOH?
- What is the impact of nOH symptoms on the patient and the caregiver?
- How do we approach the management of nOH symptoms?
- How can cardiologists and neurologists collaborate in managing patients with nOH?
For additional reference please review: Cutsforth-Gregory JK, Low PA. Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer. Neurol Ther. 2019 Dec;8(2):307-324.
© 2021 Lundbeck. All rights reserved. UBR-D-100900
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joseph William Ray, MD
Fabry disease is a progressive, genetic disorder that can cause multisystemic damage and reduce life expectancy when left undiagnosed and unmanaged, making the timely and appropriate management of Fabry disease essential. Recent clinical outcome data and real-world evidence led to the approval of Fabrazyme, a treatment option for Fabry disease. Joining Dr. Charles Turck to share that data is Dr. Joseph William Ray, an Associate Professor of Pediatrics and Director of Medical Genetics at the University of Texas Medical Branch.
For more information, please visit www.fabrazyme.com/hcp.
MAT-US-2107750-v1.0-08/2021
Host: Jennifer Caudle, DO
Guest: Keith McCrae, MD
In order to reflect the evolving management of immune thrombocytopenia (ITP), the American Society of Hematology updated their clinical practice guidelines. Here to share some of the key recommendations for the management of adult and pediatric ITP is Dr. Keith McCrae, a board-certified hematologist and an author of the 2019 ASH Guidelines.
© 2021 Amgen Inc. All rights reserved. USA-531-80829 08/21
Throughout this 8-chapter program, you’ll hear from cardiologist Dr. Rachel Bond, cardiologist and vascular medicine specialist Dr. Geoff Barnes, and patient advocate Elizabeth about the increasing prevalence of peripheral artery disease (PAD) along with key strategies for diagnosing and managing patients with PAD.
©Janssen Pharmaceuticals, Inc. 2021 08/21 cp-230791v1
Guest: Daniel Claassen, MD, MS
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 The cardinal symptoms of nOH include dizziness and lightheadedness,3 but frequently could include syncope, cognitive slowing, generalized weakness, coat-hanger (neck and shoulder) headache, fatigue, orthostatic dyspnea, blurred vision, and orthostatic angina.3 According to the Harris Poll conducted among nOH patients and their caregivers, the symptoms of nOH have a negative impact on activities of daily living. The symptoms are often minimized, poorly recognized/evaluated, or inadequately discussed and addressed.4
Patients with nOH may experience symptoms that can make daily tasks a challenge.1,5 The frequency and severity of symptomatic episodes can be unpredictable,6 and it is this unpredictability of events that contributes to a vicious cycle of nOH.1 In this cycle, fear of symptomatic events and falls may lead patients to reduce physical activity.1,5
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
- Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615-624.
- Claassen DO, Adler …
Guest: Ami B. Bhatt, MD
The COVID-19 pandemic has brought a new level of understanding and optimizing telemedicine. Here to walk us through how telehealth can help us address unmet needs in direct outpatient cardiology, how it can be enhanced with wearable technology, and more is Dr. Ami Bhatt, Director of Outpatient Cardiology and Telecardiology at the Massachusetts General Hospital Heart Center.
6/21 121907
Guest: Yehuda Handelsman, MD
Guest: Guy L. Mintz, MD
Guest: James A. Underberg, MD
Guest: Kari Uusinarkaus, MD
To learn more about the effect of persistent long-term exposure to LDL cholesterol on a patient’s risk of atherosclerotic cardiovascular disease, tune in to hear Drs Guy L. Mintz, James Underberg, Kari Uusinarkaus, and Yehuda Handelsman share their perspectives from four different specialties: cardiology, family medicine, internal medicine, and endocrinology.
6/21 121910
Host: Tracey Evans, MD
Guest: Raja Mudad, MD
TECENTRIQ® (atezolizumab), in combination with carboplatin and etoposide, is a first-line treatment option for adult patients with extensive-stage small cell lung cancer. What does this treatment path look like in clinical practice? Dr. Tracey Evans is joined by medical oncologist Dr. Raja Mudad to walk us through an example patient case that gives us a better sense of key diagnostic factors, treatment approach, and patient management.
This program is intended for US Physicians.
M-US-00010814(v1.0)
Host: David M. Simpson, MD
Guest: David R. Walega, MD
Guest: Eric J. Viel, MD, PhD
Find the full Prescribing Information here.
What are some of the current challenges in treating patients with painful diabetic peripheral neuropathy, and how can we overcome them? Explore those questions and more through the lens of patient case studies with Dr David M. Simpson, Dr Eric Viel, and Dr David Walega.
Here to walk us through the clinical trial data that led to the FDA approval of a treatment option for painful diabetic peripheral neuropathy of the feet is Dr David M. Simpson, a Professor of Neurology at the Icahn School of Medicine and Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division at Mount Sinai in New York.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
Host: Tracey Evans, MD
Guest: Raja Mudad, MD
For thirty years, there were limited therapeutic advancements leading to FDA approvals in extensive-stage small cell lung cancer (ES-SCLC). However, this all changed with the IMpower133 trial, which led to the emergence of immunotherapy as a first line treatment option in ES-SCLC. Joining Dr. Tracey Evans is medical oncologist Dr. Raja Mudad to discuss the IMpower133 trial and the reasons to consider TECENTRIQ® (atezolizumab), the first immunotherapy combination for patients with ES-SCLC.
This program is intended for US Physicians.
M-US-00010808(v1.0)
Host: David M. Simpson, MD
Guest: Rory Abrams, MD
Find the full Prescribing Information here.
The STEP trial was the first-ever study assessing the efficacy and safety of the capsaicin 8% topical system for patients living with painful diabetic peripheral neuropathy (PDPN) of the feet. Here to share key findings from the trial and what this treatment might mean for our patients are Dr. David M. Simpson, principal investigator of the STEP trial, and Dr. Rory Abrams, an expert neurologist and author of a recent high-concentration capsaicin 8% topical system review paper.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
Host: David M. Simpson, MD
Guest: Serge Perrot, MD, PhD
Dive into the data from an international trial evaluating the long-term safety and tolerability of a treatment option for painful diabetic peripheral neuropathy of the feet with Dr. David M. Simpson, a Professor of Neurology at Icahn School of Medicine at Mount Sinai, and Professor Serge Perrot, a Professor of Clinical Pharmacology at Paris Descartes University.
Find the full Prescribing Information here.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
Guest: David M. Simpson, MD
Guest: Jon T. Gertken, MD
Guest: Stephanie Simon, NP
Find the full Prescribing Information here.
There are multiple ways to incorporate the use of Qutenza, a topical treatment for painful diabetic peripheral neuropathy of the feet, into practice. Tune in to hear Dr. David M. Simpson, Dr. Jon T. Gertken, and Ms. Stephanie Simon share their best practices for administering Qutenza as well as the management of painful diabetic peripheral neuropathy of the feet.
QUTENZA® is a registered trademark of Averitas Pharma, Inc.
© 2021 Averitas Pharma, Inc. All rights reserved.
M-QZA-US-01-21-0065 June 2021
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Small cell lung cancer (SCLC) is a highly aggressive, lethal, and widely metastatic lung cancer. While therapeutic progress in SCLC has been limited over the years, immunotherapy has made some meaningful advancements in the treatment landscape. Joining Dr. Jennifer Caudle to discuss key diagnostic and therapeutic considerations such as TECENTRIQ® (atezolizumab) for 1L ES-SCLC, is Dr. Tracey Evans, Director of Thoracic Oncology Research at Lankenau Institute for Medical Research and Co-Director of the Thoracic Oncology Program at Main Line Health.
This program is intended for US Physicians.
M-US-00010802(v1.0)
Host: Joel Wedd MD, MPH
Not only is hepatocellular carcinoma (HCC) the most common primary liver cancer in adults, but it’s also the fastest-growing cause of cancer-related deaths in the US. That’s why Dr. Joel Wedd, Associate Professor of Medicine at the Virginia Commonwealth University and Medical Director of Liver Transplant at the Hume-Lee Transplant Center, is here to discuss the pathogenesis of hepatocellular carcinoma, risk factors, the importance of early-stage detection, and more.
Host: Eric Verdin, MD
Here to talk about some of the cellular changes associated with aging, how these changes manifest clinically as we age, and emerging nutritional interventions to target these changes is Dr. Eric Verdin, the President and Chief Executive Officer of the Buck Institute for Research on Aging.
Host: Jerome Lisk, MD
Guest: Merle Diamond, MD
With migraine as a major global health problem that affects over 10% of the population, approximately 1 billion globally, and about 12% in the US, now more than ever it’s vital that healthcare professionals have a deep understanding of the role of the calcitonin gene-related peptide (CGRP) and its receptor in migraine pathophysiology1,2,3. That’s why Dr. Merle Lea Diamond joins Dr. Jerome Lisk to review that and more.
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2018;392:1789-1858.
- Lipton RB, et al. Neurology. 2007;68:343-349.
- Lassen LH, et al. Cephalalgia. 2002;22:54-61.
USA-334-84583
Guest: Andy Arwari, MD
With more patients opting for home-based care over long-term, acute, and office-based care, it’s important that we align with our patients on what’s most important to them and how they want to be cared for, especially those who are nearing the end of life.
That’s why VITAS Medical Director, Dr. Andy Arwari, is here to share the purpose of goals-of-care conversations and how an app can aid in determining if an advanced illness patient is eligible for hospice.
Host: Jennifer Caudle, DO
Guest: Lauren Angelo, PharmD, MBA
Egg-based manufacturing methods for influenza vaccines have been a mainstay of production. But the recent emergence of a cell based manufacturing method changes our approach entirely. What will this paradigm shift look like? Are there new opportunities and challenges to address along the way? Here to answer that and other practical questions is Dr. Lauren Angelo, Associate Dean for Academic Affairs and an Associate Professor of Pharmacy Practice at Rosalind Franklin University of Medicine and Science College of Pharmacy.
USA-CRP-21-0030 May 2021
Guest: Caroline Hastings, MD
Guest: Raymond Y. Wang, MD
Niemann-Pick disease type C (NPC) is an ultra-rare, inherited, neurodegenerative disease with life-threatening complications. Due to its highly variable onset of neurological symptoms throughout one’s lifespan, recognizing and establishing diagnosis for NPC can be challenging for any clinician.
That’s why Drs. Caroline Hastings and Raymond Y. Wang join Dr. Jennifer Caudle to help address those challenges with a detailed look at this genetic condition, the factors underlying its variable onset and course, and strategies to improve recognition, cross-specialty communications, and time to diagnosis.
Copyright ©2021 Orphazyme A/S. All rights reserved.
Host: Jennifer Caudle, DO
Guest: Stephen I. Pelton, MD
Guest: L.J Tan, MS, PhD
Real-world effectiveness of influenza vaccines vary from year to year based on several factors. But how is real-world effectiveness measured? And what roles do the data gathered from real-world clinical trials play in estimating vaccine effectiveness? Here to answer that and other practical questions are Dr. Stephen Pelton, Professor of Pediatrics and Epidemiology at the Boston University School of Medicine and Public Health and Dr. L.J. Tan, Chief Strategy Officer for the Immunization Action Coalition and Co-Founder of the National Adult and Influenza Immunization Summit.
USA-CRP-21-0009 May 2021
Host: Matt Birnholz, MD
Guest: April W. Armstrong, MD, MPH
Guest: Laura Ferris, MD, PhD
When dermatologists and psoriasis patients fail to align on treatment expectations, this can lead to missed opportunities in achieving higher levels of skin clearance. Fortunately, utilizing certain therapeutic and counseling strategies can help dermatologists better align with their patients and improve their standards of care. Joining Dr. Matt Birnholz to share these practical strategies are Drs. April Armstrong and Laura Ferris.
VERSION 1.0 | MAY 2021 | ABBV-US-00466-MC
Guest: April Armstrong, MD, MPH
Since we’re starting to reevaluate how we think about psoriasis severity and which patients are eligible for systemic therapies, Dr. April Armstrong leading dermatologist from University of Southern California is here to walk us through how traditional classifications of disease severity may not be sufficient to reflect the full impact of psoriasis on patients.
VERSION 1.0 | APRIL 2021 | ABBV-US-00440-MC
Guest: April Armstrong, MD, MPH
Psoriasis can have significant emotional and psychosocial impact on patients. There is a need to set concrete therapeutic goals for our patients with moderate-to-severe plaque psoriasis. That’s why leading dermatologist Dr. April Armstrong from the Keck School of Medicine at USC is here to discuss how we can make clear or almost clear skin an achievable target and have a shared therapeutic outlook with patients.
VERSION 1.0 | APRIL 2021 | ABBV-US-00445-MC
Host: Jennifer Caudle, DO
Guest: Aryeh Shander, MD, FCCM, FCCP
Bleeding is the most common complication of anticoagulant use. And to better care for patients either experiencing acute bleeding or urgently needing surgery, it's critical that clinicians thoroughly understand how to assess, treat, and reverse anticoagulation. Dr. Jennifer Caudle sits down with Dr. Aryeh Shander to discuss some of the different considerations we should take into account when selecting a warfarin reversal option.
Please read full Prescribing Information for Kcentra®.
KCT-0033-APR21
Host: Jennifer Caudle, DO
Guest: Michelle Kincaid, MD
Guest: David M. Janicke, MD
What do we need to know about Kcentra®, Prothrombin Complex Concentrate (Human), and its role in coagulation factor replacement for acute deficiencies? Joining Dr. Jennifer Caudle to explore that question and more through the lens of a patient case are emergency medicine specialist Dr. David Janicke and critical care surgeon Dr. Michelle Kincaid.
Please read full Prescribing Information for Kcentra®.
KCT-0052-APR21
Host: Matt Birnholz, MD
Guest: Alexis Ogdie, MD, MSCE
Axial psoriatic arthritis (axPsA) is a challenging clinical entity to characterize, with a prevalence ranging anywhere between 12.5% and 78% of psoriatic arthritis patients because of varied definitions and inclusion criteria. To learn more about how we can better define and diagnose axPsA, Dr. Matt Birnholz is joined by Dr. Alexis Ogdie, Associate Professor of Medicine and Epidemiology at the University of Pennsylvania.
4/21 M-XAT-1400586
Host: Matt Birnholz, MD
Guest: Christopher P. Evans, M.D., F.A.C.S.
Guest: Maha Hussain, MD, FACP, FASCO
Prostate cancer is one of the most common cancers in men in the United States. In a program sponsored by Astellas and Pfizer, Drs. Maha Hussain and Christopher Evans discuss the history and how care is evolving for men with metastatic prostate cancer and non-metastatic castration-resistant prostate cancer.
This program is intended for United States health care professionals only. Drs. Hussain and Evans have recevied compensation from Astellas and Pfizer for their time.
074-0391-PM
Host: Jennifer Caudle, DO
Guest: Archana Chatterjee, MD, PhD
Since adults 65 years and older bear the greatest burden of severe disease from influenza, it’s critically important to ask ourselves the following question: what can we do to better prevent seasonal influenza infections in older adults? Here to answer that and other practical questions is Dr. Archana Chatterjee, MD, PhD, Dean of the Chicago Medical School and Vice President for Medical Affairs at Rosalind Franklin University in Chicago, IL.
USA-CRP-21-0004 January 2021
Host: Shannon L. Meeks, MD
Guest: Cindy Leissinger, MD
Pharmacovigilance begins after clinical trials end and new therapies enter everyday practice. Due to the rarity of hemophilia, participation in clinical trials has necessarily been small, and so monitoring the safety of new hemophilia treatments is especially important. Continued surveillance of adverse drug reactions (ADRs) after approval is a responsibility that falls on all members of the care team.
Dr. Shannon Meeks and Dr. Cindy Leissinger discuss the importance of safety surveillance and monitoring for novel hemophilia A therapeutics. To give a better understanding of pharmacovigilance, this activity includes animation that breaks down the process and illustrates where your ADR reports go and what happens next.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Jennifer A. Frontera, MD
Most commonly associated with respiratory symptoms, COVID-19 infections have led to a myriad of neurological symptoms such as encephalopathy and stroke. Dr. Andrew Wilner joins Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, to discuss obstacles that neurologists have faced during the COVID-19 pandemic.
Guest: Randy C. Miles, MD, MPH
There’s been a sharp decrease in breast cancer diagnoses since the beginning of the COVID-19 pandemic. But that doesn’t necessarily mean there are any fewer cases out there. Here to share how the COVID-19 pandemic has impacted breast cancer screening and how we can increase access to this essential proactive measure is Dr. Randy Miles, Clinical Service Chief in the Division of Breast Imaging at the Department of Radiology at the Massachusetts General Hospital.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nicole Lamanna, MD
The anti-apoptotic protein B-cell lymphoma 2 (BCL2) is a key regulator of the intrinsic apoptotic pathway and is often overexpressed in chronic lymphocytic leukemia (CLL) cells. That’s why BCL2 represents an important therapeutic target for CLL, and joining Dr. Charles Turck to look at Venetoclax, a treatment option that targets this protein is Dr. Nicole Lamanna, an Associate Clinical Professor of Medicine at Columbia University Medical Center in New York.
Guest: Satish R. Raj, MD, MSCI
Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 In these patients, there is insufficient compensatory peripheral release of norepinephrine, the major neurotransmitter responsible for blood pressure maintenance, upon standing or following postural change.2-4 Due to this norepinephrine deficiency, there is inadequate vasoconstriction to maintain blood pressure or cerebral blood flow.1,5 This may lead to symptoms of nOH which may increase the risk of falls and lead to serious consequences.2,3,6
Here. Dr. Satish Raj, Professor of Cardiac Sciences at the Libin Cardiovascular Institute at the University of Calgary's Cumming School of Medicine and Medical Director of Calgary Autonomic Clinic, discusses the pathogenesis of nOH, as well as the mechanisms behind therapeutic approaches to controlling its effects.
References:
- Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011:21(2) 69-72.
- Low PA. Neurogenic orthostatic hypotension: pathophysiology and diagnosis. Am J Manag Care. 2015;21(suppl 13):s248-s257.
- Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009:119(1):139-146.
- Freeman …
Host: Jennifer Caudle, DO
Guest: Coy Heldermon, MD, PhD
Guest: Heather Lau, MD, MS
Several questions are often brought to light when it comes to detecting and diagnosing Gaucher disease, such as how does it present, what genetic factors to consider, and how to go about making an accurate diagnosis. Here to answer those and other questions are practicing hematologist oncologist Dr. Coy Heldermon and neurogeneticist Dr. Heather Lau.
For more information on the diagnostic and therapeutic landscape for Gaucher disease, including access to Sanofi Genzyme Rare Disease Registries, visit Gauchercare.com/hcp, a Sanofi Genzyme website.
MAT-US-2024074 2/2021
Host: Jennifer Caudle, DO
Guest: Casey Lafferty, DO
Guest: Eder Hernández, DMSc, PA-C
With the ongoing COVID-19 pandemic threatening our health and adding burden to our healthcare system, it’s more important than ever to educate patients on the flu and its symptoms. Here to share tips on how we can help prepare for, diagnose and treat flu this season are Dr. Casey Lafferty and Physician Assistant Doctorate Dr. Eder Hernández.
This information is intended for US audiences only.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understandings of the AML genomic landscape, it’s become possible to develop targeted AML therapies. Joining Dr. Charles Turck to explore Venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua Stolker, MD
Patients with type 2 diabetes face a higher risk of cardiovascular morbidity and mortality than adults without diabetes. How does this understanding specifically affect the way cardiologists manage their patients with type 2 diabetes? Joining Dr. Charles Turck to explore recently updated recommendations and their impacts on cardiology practice is interventional cardiologist Dr. Joshua Stolker.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00435 February 2021
Guest: Hemal Gada, MD
Guest: Vijay Iyer, MD, PhD, FACC
TAVR-related stroke is a real risk that can seriously impact your patients' quality of life. In this video, Drs. Hemal Gada and Vijay Iyer sit down to discuss the effects of stroke, the role of cerebral embolic protection, and the importance of protecting patients' brains.
Physicians in this episode were compensated for their participation.
Media provided courtesy of Boston Scientific or its affiliates.
Guest: Joshua Stolker, MD
The 2020 American College of Cardiology Expert Consensus Decision Pathway provides a change in mindset for the cardiology field when it comes to treating patients with type 2 diabetes with established cardiovascular disease. Here to walk us through these updated recommendations is Dr. Joshua Stolker, an interventional cardiologist at Mercy Clinic Heart and Vascular in Saint Louis, Missouri.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00430 January 2021
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lee P. Shulman, MD, FACMG, FACOG
Cervical cancer is the fourth most common cancer in women worldwide, which makes it essential for us to keep ahead of advances in cervical cancer prevention—advances like a biomarker-based cytology test. Here to discuss this and other recent advancements in cervical cancer screening is Dr. Lee Shulman, the Anna Ross Lapham Professor in Obstetrics and Gynecology in the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: Sripal Bangalore, MD, MHA
For patients who have recently experienced a myocardial infarction, LDL cholesterol management is critical to help reduce the risk of recurrent CV events. At a time of the COVID-19 pandemic, when patient behavior and clinical practice methods are impacted, what can we do to improve CV outcomes for these patients? Join Drs. Pam Taub and Sripal Bangalore as they explore why patients with a recent myocardial infarction occurring within the previous 12 months are among the highest risk for recurrent CV events and what can be done to better manage that risk.
©2020 Amgen Inc. All rights reserved. USA-145-82480 12/20
Guest: Roger S. McIntyre, MD, FRCPC
Up to a quarter of patients being treated for major depressive disorder in a primary care setting may actually have bipolar disorder.1,2 A significant number of patients with bipolar disorder are receiving a misdiagnosis of unipolar depression.3 The consequences of misdiagnosis can be substantial.4 It’s critical for primary care providers to stay alert for historical and emerging symptoms of bipolar disorder in undiagnosed patients, gain expertise in providing ongoing treatment to diagnosed patients, and know how to manage comorbidities, explains Dr. Roger McIntyre Professor of Psychiatry and Pharmacology at the University of Toronto, in an article entitled, Bipolar Depression: The Clinical Characteristics and Unmet Needs of a Complex Disorder.
The open access article is available online at the journal's website:
Roger S. McIntyre & Joseph R. Calabrese (2019) Biploar depression: the clinical characteristics and unmet needs of a complex disorder, Current Medical Research and Opinion, 35:11, 1993-2005, DOI: 10.1080/03007995.2019.1636017
References1. Hirschfeld RMA, Cass AR, Holt DCL, et al. J Am Board Fam Pract. 2005;18(4):233-239.
2. Olfson M, Das AK, Gameroff MJ, et al. Am J Psychiatry. 2005;162:2146-2151.
3. Berk M, Hallam K, Lucas N, et al. Med J …
Host: Jennifer Caudle, DO
Guest: Roger S. McIntyre, MD, FRCPC
Nationally, approximately 43% of family physicians are providing mental health care, and approximately 25% of patients with depression in a primary care setting may actually have bipolar disorder.1-3 A possible cause of misdiagnosis is that depressive episodes are commonly the initial presentation of the disease.4 Faster recognition and more accurate management of patients with bipolar depression is absolutely critical, explains Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto, in an article entitled, Bipolar Depression: The Clinical Characteristics and Unmet Needs of a Complex Disorder.
The open access article is available online at the journal’s website:
Roger S. McIntyre & Joseph R. Calabrese (2019) Bipolar depression: the clinical characteristics and unmet needs of a complex disorder, Current Medical Research and Opinion, 35:11, 1993-2005, DOI: 10.1080/03007995.2019.1636017
References
1. Hirschfeld RMA, Cass AR, Holt DCL, et al. J Am Board Fam Pract. 2005;18(4):233-239.
2. Olfson M, Das AK, Gameroff MJ, et al. Am J Psychiatry. 2005;162:2146-2151.
3. Xierali IM, Tong ST, Petterson SM, et al. J Am Board Fam Pract. 2013;26(2):114-115.
4. Mitchell PB, Goodwin GM, Johnson GF, et al. Bipolar Disord. 2008;10:144-152.
Host: Jennifer Caudle, DO
Guest: Carlos Campos, MD, MPH
Guest: Pablo F. Mora, MD
Guest: Joshua Stolker, MD
Each year, the American Diabetes Association (ADA) releases updates to their Standards of Medical Care in Diabetes. Joining Dr. Jennifer Caudle to share their insights on what’s updated in the 2020 treatment algorithm is endocrinologist Dr. Pablo Mora, cardiologist Dr. Joshua Stolker, and family medicine specialist Dr. Carlos Campos.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00339 October 2020
Guest: Pablo F. Mora, MD
The glycemic control algorithm that’s part of the American College of Endocrinology Consensus Statement for 2020 is separated into several parts, and here to break them down for us is Dr. Pablo Mora, Clinical Professor with the Division of Endocrinology at the University of Texas Western Medical Center of Dallas.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00336 October 2020
Host: Jennifer Caudle, DO
Guest: Lisa A. Coco, CRNP
Guest: Deborah Hinnen, APN, BC-ADM, CDCES, FAAN
Guest: Davida F. Kruger, CNP
When a patient with diabetes has cardiovascular disease, they’re at greater risk for morbidity and mortality. That’s why the American Diabetes Association’s 2020 Standards of Medical Care in Diabetes aim to address this and other health risks, and here to walk us through this new treatment algorithm are nurse practitioners Lisa Coco, Debbie Hinnen, and Davida Kruger.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00343 October 2020
Host: Richard K. Bogan, MD
While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night.
Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Guest: Paul Doghramji, MD
Excessive daytime sleepiness (EDS) in obstructive sleep apnea (OSA) is frequently underrecognized, as patients may not understand the extent of their sleepiness and EDS does not always correlate with other OSA symptoms. However, it’s important for physicians to identify EDS as it may lead to adverse consequences.
Dr. Paul P. Doghramji, Senior Family Physician at Collegeville Family Practice and Medical Director of Health Services at Ursinus College, discusses identifying EDS and the vital role assessment tools like the Epworth Sleepiness Scale can have in practice.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Guest: Richard K. Bogan, MD
Emerging science can help us better understand the link between obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS). While many factors, such as insufficient sleep, medication, or comorbid disorders, can cause your patients with OSA to feel sleepy, chronic sleep disruption and chronic intermittent hypoxia associated with OSA may also contribute to EDS.
Here to discuss the important physiologic changes to gray and white matter that may occur in OSA and lead to EDS is Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.
In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1
Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2
Visit TagrissoHCP.com to learn what these data could mean for your patients.
FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …
Host: Matt Birnholz, MD
Guest: Carol Vargo, MHS
Guest: Sheryl Hirsch, MD, FAAP
Guest: Thomas Eppes, MD
The American Medical Association is one of the leading medical organizations across the country that have been working to provide physicians with the tools and resources they need to continue caring for patients and to keep their practices financially afloat amid the COVID-19 pandemic. Joining Dr. Matt Birnholz to review the AMA’s guidance for reopening practices during the pandemic and how some practices have begun to reopen are Carol Vargo from the AMA, pediatrician Dr. Sheryl Hirsch, and family physician Dr. Thomas Eppes.
Host: Matt Birnholz, MD
COVID-19 has irreversibly altered the progression track for the next generation of physicians, with cancellations of Match Day events, Board exams, and clinical rotations in effect. Now an increasing number of entities are calling on medical students to join front-line efforts to combat the virus.
Published March 23, 2020
Guest: Jason Day
Guest: Dening Day
Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3
In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results.
Share this video and more with your patients by visiting TestLungCancer.com.
References:
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J …
Host: Jennifer Caudle, DO
Guest: Michael Lewiecki, MD, FACP, FACE
With an incidence rate of more than 750,000 per year, vertebral fractures contribute significantly to morbidity and mortality rates in osteoporosis patients, particularly those who have sustained a VCF in the past. In this new segment, we will hear from Dr. Michael Lewiecki, as he examines this debilitating issue. Dr. Lewiecki is the Director of the New Mexico Clinical Research and Osteoporosis Center; and, Clinical Assistant Professor of Medicine at UNM School of Medicine in Albuquerque, New Mexico.